DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-3.45%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$334M
AUM Growth
+$334M
(-6.1%)
Cap. Flow
-$2.99M
Cap. Flow
% of AUM
-0.9%
Top 10 Holdings %
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11
Top Buys
| 1 |
Cytokinetics
CYTK
|
$3.26M |
| 2 |
Century Therapeutics
IPSC
|
$2.89M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$2.51M |
| 4 |
AtriCure
ATRC
|
$2.22M |
| 5 |
Revolution Medicines
RVMD
|
$2.12M |
Top Sells
| 1 |
Fate Therapeutics
FATE
|
$5.56M |
| 2 |
89bio
ETNB
|
$4.13M |
| 3 |
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
|
$3.65M |
| 4 |
Viking Therapeutics
VKTX
|
$3.37M |
| 5 |
Biohaven
BHVN
|
$2.15M |
Sector Composition
| 1 | Healthcare | 81.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CBAY
76
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-171,059
| Closed | -$1.07M |
|
77
SCYNEXIS
SCYX
$35.2M
| – | – |
-153,269
| Closed | -$239K |
|
78
MacroGenics
MGNX
$121M
| – | – |
-39,879
| Closed | -$268K |
|
|
79
Fate Therapeutics
FATE
$115M
| – | – |
-550,940
| Closed | -$5.56M |
|
|
80
89bio
ETNB
$1.37B
| – | – |
-324,173
| Closed | -$4.13M |
|
81
Biomea Fusion
BMEA
$114M
| – | – |
-34,625
| Closed | -$292K |
|
|
AFMD
82
DELISTED
Affimed
AFMD
| – | – |
-686,282
| Closed | -$851K |
|
83
Black Diamond Therapeutics
BDTX
$164M
| – | – |
-97,500
| Closed | -$176K |
|